Skip to main content
Erschienen in: International Journal of Clinical Oncology 9/2021

03.06.2021 | Original Article

Development of a novel apoptosis-based tumor regression grade to assess the efficacy of preoperative chemoradiotherapy for rectal cancer: a retrospective single-center study

verfasst von: Kosuke Ozaki, Kazushige Kawai, Hiroaki Nozawa, Kazuhito Sasaki, Koji Murono, Soichiro Ishihara

Erschienen in: International Journal of Clinical Oncology | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Preoperative chemoradiotherapy is used preferably for locally advanced rectal cancer, followed by a watch-and-wait strategy for cases showing clinical complete response. However, there is a discordance between pathological and clinical complete response rates. We aimed to propose a tumor regression grade (TRG) that truly reflects the therapeutic effects of preoperative chemoradiotherapy in locally advanced rectal cancer.

Methods

Overall, 293 consecutive patients with T3/T4a/T4b rectal cancer who underwent chemoradiotherapy followed by radical surgery between Sep 2003 and Dec 2018 were retrospectively reviewed. We assessed apoptosis using M30 cytoDEATH immunostaining and correlated that with conventional TRG (convTRG) evaluated using hematoxylin–eosin staining, and created a new TRG by evaluating apoptosis and convTRG. The modified TRG1-4 (modifTRG) classification was as follows: modifTRG1 comprised poor TRG, modifTRG2 moderate TRG, modifTRG3 good TRG, modifTRG4 complete apoptosis and convTRG3 (pathological complete response). We assessed the overall survival, relapse-free survival, and local recurrence rate.

Results

Pathological complete response rate was 10.6% when evaluated using conventional staining. Using M30 staining, apoptosis was observed in the residual disease in convTRG 1a 0%, convTRG 1b 0.3%, convTRG 2 9.2%. Combining the two, modifTRG4 was observed in 20.1%. The survival rates were similar between modifTRG4 and convTRG3, suggesting that modifTRG4 was equivalent to pathological complete response. However, in multivariate analysis, modifTRG but not convTRG was an independent risk factor for local and distant recurrences.

Conclusion

The proposed modifTRG truly reflected the therapeutic effects of chemoradiotherapy and may be superior to the convTRG to stratify rectal cancer patients treated with chemoradiotherapy.
Literatur
1.
Zurück zum Zitat BensonVenook ABAP, Bekaii-Saab T et al (2015) Rectal cancer, version 2.2015. J Natl Compr Canc Netw 13:719–728CrossRef BensonVenook ABAP, Bekaii-Saab T et al (2015) Rectal cancer, version 2.2015. J Natl Compr Canc Netw 13:719–728CrossRef
2.
Zurück zum Zitat Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:22–40CrossRef Glynne-Jones R, Wyrwicz L, Tiret E et al (2017) Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:22–40CrossRef
3.
Zurück zum Zitat Habr-Gama A, Perez RO, Nadalin W et al (2014) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–718CrossRef Habr-Gama A, Perez RO, Nadalin W et al (2014) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240:711–718CrossRef
4.
Zurück zum Zitat Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 56:1109–1117CrossRef Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 56:1109–1117CrossRef
5.
Zurück zum Zitat Kong JC, Guerra GR, Warrier SK et al (2017) Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 60:335–345CrossRef Kong JC, Guerra GR, Warrier SK et al (2017) Outcome and salvage surgery following “watch and wait” for rectal cancer after neoadjuvant therapy: a systematic review. Dis Colon Rectum 60:335–345CrossRef
6.
Zurück zum Zitat Habr-Gama A (2006) Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 8(Suppl 3):21–24CrossRef Habr-Gama A (2006) Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 8(Suppl 3):21–24CrossRef
7.
Zurück zum Zitat Renehan AG, Malcomson L, Emsley R et al (2016) Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 17:174–183CrossRef Renehan AG, Malcomson L, Emsley R et al (2016) Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 17:174–183CrossRef
8.
Zurück zum Zitat Habr-Gama A, Gama-Rodrigues J, São Julião GP et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88:822–828CrossRef Habr-Gama A, Gama-Rodrigues J, São Julião GP et al (2014) Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol Biol Phys 88:822–828CrossRef
9.
Zurück zum Zitat Xu L, Cai S, Xiao T et al (2017) Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8 year retrospective single-institutional study. Colorectal Dis 19:O263–O271CrossRef Xu L, Cai S, Xiao T et al (2017) Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8 year retrospective single-institutional study. Colorectal Dis 19:O263–O271CrossRef
10.
Zurück zum Zitat Kong JC, Guerra GR, Warrier SK et al (2018) Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis 20:574–585CrossRef Kong JC, Guerra GR, Warrier SK et al (2018) Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis. Colorectal Dis 20:574–585CrossRef
11.
Zurück zum Zitat Martin ST, Heneghan HM, Winter DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99:918–928CrossRef Martin ST, Heneghan HM, Winter DC (2012) Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99:918–928CrossRef
12.
Zurück zum Zitat Smith KD, Tan D, Das P et al (2010) Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 251:261–264CrossRef Smith KD, Tan D, Das P et al (2010) Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg 251:261–264CrossRef
13.
Zurück zum Zitat Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696CrossRef Rödel C, Martus P, Papadoupolos T et al (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23:8688–8696CrossRef
14.
Zurück zum Zitat Felipe L, de Campos-Lobato DP, Geisler A, da Luz Moreira, et al (2011) Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 15:444–450CrossRef Felipe L, de Campos-Lobato DP, Geisler A, da Luz Moreira, et al (2011) Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 15:444–450CrossRef
15.
Zurück zum Zitat Petrelli F, Sgroi G, Sarti E et al (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 263:458–464CrossRef Petrelli F, Sgroi G, Sarti E et al (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 263:458–464CrossRef
16.
Zurück zum Zitat Lefevre JH, Mineur L, Kotti S et al (2016) Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34:3773–3780CrossRef Lefevre JH, Mineur L, Kotti S et al (2016) Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34:3773–3780CrossRef
17.
Zurück zum Zitat Saraste A, Pulkki K (2000) Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45:528–537CrossRef Saraste A, Pulkki K (2000) Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45:528–537CrossRef
18.
Zurück zum Zitat Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H et al (1995) In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21:1465–1468PubMed Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H et al (1995) In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 21:1465–1468PubMed
19.
Zurück zum Zitat Tateyama H, Tada T, Hattori H et al (1998) Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Arch Pathol Lab Med 122:252–255PubMed Tateyama H, Tada T, Hattori H et al (1998) Effects of prefixation and fixation times on apoptosis detection by in situ end-labeling of fragmented DNA. Arch Pathol Lab Med 122:252–255PubMed
20.
Zurück zum Zitat Hawkins NJ, Lees J, Ward RL (1997) Detection of apoptosis in colorectal carcinoma by light microscopy and in situ end labelling. Anal Quant Cytol Histol 19:227–232PubMed Hawkins NJ, Lees J, Ward RL (1997) Detection of apoptosis in colorectal carcinoma by light microscopy and in situ end labelling. Anal Quant Cytol Histol 19:227–232PubMed
21.
Zurück zum Zitat Leers MP, Kölgen W, Björklund V et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567–572CrossRef Leers MP, Kölgen W, Björklund V et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567–572CrossRef
22.
Zurück zum Zitat Carr NJ (2000) M30 expression demonstrates apoptotic cells, correlates with in 2situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124:1768–1772CrossRef Carr NJ (2000) M30 expression demonstrates apoptotic cells, correlates with in 2situ end-labeling, and is associated with Ki-67 expression in large intestinal neoplasms. Arch Pathol Lab Med 124:1768–1772CrossRef
23.
Zurück zum Zitat Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138:1379–1394CrossRef Caulin C, Salvesen GS, Oshima RG (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138:1379–1394CrossRef
25.
Zurück zum Zitat de Bruin EC, van de Velde CJH, van de Pas S et al (2006) Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 12:6432–6436CrossRef de Bruin EC, van de Velde CJH, van de Pas S et al (2006) Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 12:6432–6436CrossRef
26.
Zurück zum Zitat Saigusa S, Inoue Y, Tanaka K et al (2014) Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol 2:99–104CrossRef Saigusa S, Inoue Y, Tanaka K et al (2014) Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy. Mol Clin Oncol 2:99–104CrossRef
27.
Zurück zum Zitat Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687CrossRef Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13:679–687CrossRef
28.
Zurück zum Zitat Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780CrossRef Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29:2773–2780CrossRef
29.
Zurück zum Zitat Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644CrossRef Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644CrossRef
30.
Zurück zum Zitat O’Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol 32:1927–1934CrossRef O’Connell MJ, Colangelo LH, Beart RW et al (2014) Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from national surgical adjuvant breast and bowel project trial R-04. J Clin Oncol 32:1927–1934CrossRef
31.
Zurück zum Zitat Zhao L, Liu R, Zhang Z et al (2016) Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis 18:763–772CrossRef Zhao L, Liu R, Zhang Z et al (2016) Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis 18:763–772CrossRef
32.
Zurück zum Zitat Kuo LJ, Chern MC, Tsou MH et al (2005) Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 48:23–28CrossRef Kuo LJ, Chern MC, Tsou MH et al (2005) Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 48:23–28CrossRef
33.
Zurück zum Zitat Iafrate F, Laghi A, Paolantonio P et al (2006) Preoperative staging of rectal cancer with MR Imaging: correlation with surgical and histopathologic findings. Radiographics 26:701–714CrossRef Iafrate F, Laghi A, Paolantonio P et al (2006) Preoperative staging of rectal cancer with MR Imaging: correlation with surgical and histopathologic findings. Radiographics 26:701–714CrossRef
34.
Zurück zum Zitat Shanmugan S, Arrangoiz R, Nitzkorski JR et al (2012) Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Ann Surg Oncol 19:2178–2185CrossRef Shanmugan S, Arrangoiz R, Nitzkorski JR et al (2012) Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT. Ann Surg Oncol 19:2178–2185CrossRef
Metadaten
Titel
Development of a novel apoptosis-based tumor regression grade to assess the efficacy of preoperative chemoradiotherapy for rectal cancer: a retrospective single-center study
verfasst von
Kosuke Ozaki
Kazushige Kawai
Hiroaki Nozawa
Kazuhito Sasaki
Koji Murono
Soichiro Ishihara
Publikationsdatum
03.06.2021
Verlag
Springer Singapore
Erschienen in
International Journal of Clinical Oncology / Ausgabe 9/2021
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-021-01948-2

Weitere Artikel der Ausgabe 9/2021

International Journal of Clinical Oncology 9/2021 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.